Restricted accessArticle commentaryFirst published online 2025
Letter to the Editor Regarding “Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study”
MazzantiCParoliMSantoboniG, et al.Ixekizumab retention rate and predictors of treatment persistence in psoriatic arthritis: results of an Italian multicenter study. J Psoriasis Psoriatic Arthritis. doi:10.1177/24755303251342503. 2025. Online ahead of print.
2.
Rodriguez GoicoecheaMTejedor TejadaEBorrás-BlascoJ. Persistence, current state of the art. Farm Hosp. 2023;47(S1):S1130-S1134. doi:10.7399/fh.13403
3.
de la Cueva DobaoPNotarioJFerrándizC, et al.Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology. 2019;33(7):1214-1223. doi:10.1111/jdv.15468
4.
Borrás-BlascoJRamírez-HerráizENavarro RuizA. El valor de la persistencia en el modelo de la Medicina 5P en enfermedades crónicas. J Healthc Qual Res. 2023;38(6):345-348. doi:10.1016/j.jhqr.2023.05.002
5.
Borrás-BlascoJRamírez-HerráizENavarro-RuizA. Influencia de la adherencia en el valor de persistencia dentro de la Medicina 6P. J Healthc Qual Res. 2025;40(1):101123. doi:10.1016/j.jhqr.2024.101123
6.
Borrás-BlascoJRamírez-HerráizENavarro-RuizA. Integration of persistence in the 5P-medicine approach for age-related chronic diseases. International Journal for Quality in Health Care. 2024;36(1):mzae026. doi:10.1093/intqhc/mzae026
7.
Valcuende-RosiqueABorrás-BlascoJMartínez-BadalSCortesXAparicio-RubioCCasterá-MelchorE. Evaluation of persistence, retention “rate” and prescription pattern of original infliximab and infliximab CT-P13 in biologic-naïve patients with ulcerative colitis. Farmacia hospitalaria: organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2022;46(6):296-300. doi:10.7399/fh.13106
8.
Borrás-BlascoJCornejoSValcuende-RosiqueA, et al.Persistence after switching from adalimumab biosimilar MSB11022 to adalimumab biosimilar GP2017 in patients with chronic inflammatory rheumatic diseases. J Pharm Technol. 2024;40(2):123-130. doi:10.1177/87551225231222858
9.
Borrás-BlascoJCornejoSValcuende-RosiqueAAlcaláRBonoAN. Longterm persistence with secukinumab in patients with moderate-to-severe psoriasis. Farm Hosp. 2025;49(1):45-52. doi:10.7399/fh.13621
10.
Borrás-BlascoJAlcalaRValcuende-RosiqueACornejoS. Long-term real-world persistence of guselkumab in patients with moderate-tosevere psoriasis. Actas Dermosifiliogr. 2025. In press.
